PPARD and sarcoma: Moreover, the PPAR-δ alteration also shows a significant co‐occurrence with each of these same checkpoints when examining rectum adenocarcinoma, melanoma, sarcoma, uterine corpus endometrial carcinoma and lung adenocarcinoma samples (Figure 9).